HomeNewsTrendsEntertainmentCOVID-19 impact: If Rajkumar Rao's Roohi succeeds, it will be Bollywood's first hit after a year

COVID-19 impact: If Rajkumar Rao's Roohi succeeds, it will be Bollywood's first hit after a year

The film so far has been able to collect Rs 16.75 crore which is the highest for any Bollywood film in the last one year.

March 21, 2021 / 16:04 IST
Story continues below Advertisement
Roohi starring Rajkumar Rao and Janhvi Kapoor which released on March 11 became the first major Bollywood release in 2021. Before Roohi, only smaller films released in theatres due to COVID-19 impact on the exhibition business. Image: Twitter
Roohi starring Rajkumar Rao and Janhvi Kapoor which released on March 11 became the first major Bollywood release in 2021. Before Roohi, only smaller films released in theatres due to COVID-19 impact on the exhibition business. Image: Twitter

A lot of hopes are pinned on the success of the recently released Roohi starring Rajkumar Rao and Janhvi Kapoor, which has shifted gears for the box office business.

Bollywood did offer a few releases between November last year and February this year. There was Diljit Dosanjh's Suraj Pe Mangal Bhari that was released last year on November 13 and Kiara Advani's Indoo Ki Jawani which was released on December 10 and Madam Chief Minister, released on January 21 this year. But none of these releases could make any mark at the box office.

Story continues below Advertisement

On the other hand, right from the beginning despite negative reviews, Roohi has been able to get audience in large numbers to the theatres and is emerging as a strong venture at the box office.

The film so far has been able to collect Rs 16.75 crore which is the highest for any Bollywood film in the last one year. Also, Roohi has managed to grab this total in 10 days of its release. The film had hit theatres on March 11.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show